华森制药
(002907)
| 流通市值：43.74亿 | | | 总市值：59.13亿 |
| 流通股本：3.09亿 | | | 总股本：4.18亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 271,460,383.5 | 297,753,191.04 | 442,749,199.98 | 437,564,819.14 |
| 应收票据及应收账款 | 301,085,737.88 | 280,010,390.9 | 310,975,691.64 | 245,463,399.79 |
| 其中：应收票据 | 88,042,735.91 | 88,115,033.11 | 93,917,635 | 76,099,789.17 |
| 应收账款 | 213,043,001.97 | 191,895,357.79 | 217,058,056.64 | 169,363,610.62 |
| 预付款项 | 5,714,297.89 | 8,375,398.8 | 6,997,166.12 | 5,642,520.46 |
| 其他应收款合计 | 4,468,387.93 | 4,266,954.54 | 5,273,524.49 | 4,084,340.85 |
| 存货 | 149,299,692.71 | 135,589,158.57 | 136,787,352.91 | 151,676,648.09 |
| 其他流动资产 | 81,534,374.64 | 162,759,979.46 | 50,148,945.61 | 50,207,205.82 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,013,977,367.68 | 958,850,580.15 | 952,931,880.75 | 894,638,934.15 |
| 非流动资产: | | | | |
| 长期股权投资 | 18,570,090.07 | 19,374,769.57 | 21,570,931.5 | 21,942,645.29 |
| 其他非流动金融资产 | 72,728,627.97 | 72,933,396.46 | 76,464,347.13 | 76,443,252.9 |
| 投资性房地产 | 68,656,482.27 | 69,477,422.45 | 70,298,362.63 | 71,156,742.71 |
| 固定资产 | 530,437,896.82 | 539,855,482.79 | 551,589,246.82 | 567,396,745.39 |
| 在建工程 | 23,460,639.23 | 23,380,412.81 | 26,609,087.37 | 25,776,293.54 |
| 使用权资产 | 144,670.21 | 177,062.98 | 196,379.26 | 241,848.53 |
| 无形资产 | 123,736,741.26 | 128,367,224.39 | 120,082,339.06 | 107,136,440.31 |
| 开发支出 | 32,586,467.54 | 28,320,349.48 | 37,246,004.11 | 51,804,697.38 |
| 长期待摊费用 | 7,449,833.21 | 7,924,769.89 | 8,537,608 | 9,150,446.11 |
| 递延所得税资产 | 14,169,986.85 | 13,543,405.84 | 14,157,233.57 | 15,688,179.09 |
| 其他非流动资产 | 5,797,494.35 | 13,633,944.34 | 10,436,655.59 | 10,077,663.74 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 897,738,929.78 | 916,988,241 | 937,188,195.04 | 956,814,954.99 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,911,716,297.46 | 1,875,838,821.15 | 1,890,120,075.79 | 1,851,453,889.14 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 73,596,084.42 | 64,902,187.55 | 64,538,765.46 | 55,232,683 |
| 应付账款 | 73,596,084.42 | 64,902,187.55 | 64,538,765.46 | 55,232,683 |
| 预收款项 | 1,190,670.23 | 1,268,595.45 | 1,216,841.64 | 1,264,826.49 |
| 合同负债 | 4,119,518.65 | 2,399,364.25 | 2,228,810.04 | 4,426,458.03 |
| 应付职工薪酬 | 7,963,539.76 | 7,752,781.5 | 7,035,777.98 | 23,451,911.41 |
| 应交税费 | 13,207,096.1 | 6,507,348.82 | 11,092,334.57 | 6,914,477.44 |
| 其他应付款合计 | 106,685,525.68 | 106,528,929.16 | 102,417,369.57 | 96,674,184.45 |
| 一年内到期的非流动负债 | 105,163.24 | 70,108.83 | 64,823.28 | 142,075.36 |
| 其他流动负债 | 664,735.32 | 304,590.96 | 204,309.98 | 570,743.48 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 207,532,333.4 | 189,733,906.52 | 188,799,032.52 | 188,677,359.66 |
| 非流动负债: | | | | |
| 租赁负债 | 44,518.1 | 115,988.01 | 121,053.31 | 139,882.78 |
| 递延收益 | 45,078,946.68 | 39,535,053.92 | 41,275,286.58 | 43,034,299.24 |
| 递延所得税负债 | 1,783,184.79 | 1,796,584.09 | 1,624,023.78 | 1,681,340.03 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 46,906,649.57 | 41,447,626.02 | 43,020,363.67 | 44,855,522.05 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 254,438,982.97 | 231,181,532.54 | 231,819,396.19 | 233,532,881.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 417,596,314 | 417,596,314 | 417,596,314 | 417,596,314 |
| 资本公积 | 459,181,384.65 | 459,031,717.45 | 458,732,383.04 | 458,732,383.04 |
| 其他综合收益 | -239,580.56 | 36,131.25 | -37,315 | -65,735.1 |
| 盈余公积 | 92,966,643.89 | 92,966,643.89 | 92,966,643.89 | 92,966,643.89 |
| 未分配利润 | 687,772,552.51 | 675,026,482.02 | 689,042,653.67 | 648,691,401.6 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,657,277,314.49 | 1,644,657,288.61 | 1,658,300,679.6 | 1,617,921,007.43 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,657,277,314.49 | 1,644,657,288.61 | 1,658,300,679.6 | 1,617,921,007.43 |
| 负债和股东权益合计 | 1,911,716,297.46 | 1,875,838,821.15 | 1,890,120,075.79 | 1,851,453,889.14 |
| 公告日期 | 2024-10-29 | 2024-08-22 | 2024-04-29 | 2024-04-10 |
| 审计意见(境内) | | | | 标准无保留意见 |